Related Content
February 8, 2016 — Stentys announced the first distribution agreements for its drug-eluting stent for treating below-the ...
January 8, 2016 — In December, Stentys announced completion of patient enrollment in DESSOLVE III. The 1,400-patient ...
October 1, 2015 — Stentys announced that the company’s drug-eluting stent received CE Mark for treatment of below-the ...
June 18, 2015 - Stentys announced in April that it received CE Marking for its new Self-Apposing stent system ahead of ...
June 17, 2015 - Stentys announced that the findings of the first Xposition clinical experience, as part of the SETUP ...
February 17, 2015 — Micell Technologies, Inc. announced the commercial availability of the MiStent sirolimus-eluting ...
January 8, 2015 — Stentys announced that the Self-Apposing Stent has been implanted more than 10,000 times in patients ...
July 21, 2014 – Stentys announced the publication of an article in the Journal of the American College of Cardiology ...
May 23, 2014 — Stentys presented final results from the APPOSITION IV study of its new self-apposing sirolimus-eluting ...
January 6, 2014 — Stentys, developer of the world's first self-apposing stent to treat acute myocardial infarction (AMI) ...